A carregar...
Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study
Ofatumumab, the human CD20 monoclonal antibody that binds a distinct epitope from rituximab, has demonstrated clinical benefit as monotherapy for patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab (FA-ref) and patients refractory to fludarabine with bulky (> 5 cm...
Na minha lista:
| Publicado no: | Blood |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society of Hematology
2011
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4916553/ https://ncbi.nlm.nih.gov/pubmed/21856867 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-04-348656 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|